Drug Type Biological products |
Synonyms STLX 2012, STLX2012 |
Target |
Action modulators |
Mechanism IL1RAP modulators(Interleukin-1 receptor accessory protein modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Myelomonocytic Leukemia | Preclinical | United States | 01 Aug 2025 | |
Myelodysplastic Syndromes | Preclinical | United States | 01 Aug 2025 | |
Myelofibrosis | Preclinical | United States | 01 Aug 2025 | |
Systemic Mastocytosis | Preclinical | United States | 01 Aug 2025 | |
Acute Myeloid Leukemia | Preclinical | United States | 13 Sep 2024 | |
Solid tumor | Preclinical | United States | 13 Sep 2024 |